P935
Assessment of pulmonary hypertension in patients over 70
Christopher Valerio1, Benjamin Schreiber1, Clive Handler1,
Christopher Denton2, John Coghlan 1.
1Pulmonary Hypertension, Royal Free Hospital, London, United Kingdom; 2Rheumatology, Royal Free Hospital & UCL Medical School, London, United Kingdom

Background: Recent registry data suggests that the average age of patients with PAH is rising. Pulmonary hypertension affects elderly people and there is increasing prevalence of cardiac and respiratory disease with age.

Methods: We report the findings for 120 consecutive patients aged over 70 referred to a tertiary service during 2008-09 for invasive haemodynamic studies to confirm or exclude a diagnosis of pulmonary hypertension.

Results: Four patients died within 30 days of referral and before being assessed, 15 patients did not undergo cardiac catheterisation. 50% of those assessed had an associated connective tissue disease. 36 patients had resting pulmonary artery pressures <25mmHg, eleven with respiratory and ten with cardiac disease to explain their symptoms. 65 patients were diagnosed with pulmonary hypertension following invasive studies: 19 related to left heart disease, 7 related to chronic lung disease, 7 CTEPH, five mixed aetiology, and 27 PAH. Three patients with idiopathic PAH, one case associated with an atrial septal defect, 23 with connective tissue disease. Follow up log(10)NT-proBNP testing in 24 patients with PAH showed a significant reduction at 12 months (-0.21, p<0.05 students’ t-test).

Conclusion: Pulmonary hypertension of all types may be present in older patients. Thorough assessment may provide insight into the drivers of symptoms in older patients and help to guide treatment, which can be successful.

P936
Pulmonary hypertension in a district general hospital
Yan-Pin Lin, Dominic Davenport, Natasha Shrikrishna, Abigail Cole,
Harpreet Ram. Respiratory Department, St. Richard’s Hospital, Western Sussex Hospitals NHS Trust, Chichester, United Kingdom

Introduction: There is an increasing awareness to identify patients with pulmonary hypertension (PH). Classification of the underlying cause defines further management and referral to specialist centres.

Aim: To assess the burden of PH at St Richard’s Hospital, which serves a population of 230,000.

Methods: All departmental transthoracic echocardiographs (TTEs) between 1st January 2009 and 30th June 2009 were reviewed using ERS suggested criteria to identify patients with possible PH and likely PH. Further investigations were reviewed to identify the underlying aetiology in those with likely PH.

Results: A total of 2038 TTEs were reviewed. 93 (5%) had likely PH with a pulmonary artery systolic pressure (PASP) of >50mmHg. 624 (31%) had possible PH with either the presence of additional echocardiographic variables suggestive of PH or a PASP 37-50mmHg.

Of those with likely PH, 48% were male and 52% were female. The median age was 85 years (range 52-98). The overall mortality rate was 39% at 1 year and 58% at 2 years. Only 13% had right heart catheterisation locally.

Further Investigations In Patients Without Significant Left Heart (LH) Disease on TTE

<table>
<thead>
<tr>
<th>Percentage of Patients (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HRCT Chest</td>
</tr>
<tr>
<td>Other CT Chest</td>
</tr>
<tr>
<td>CTPA</td>
</tr>
<tr>
<td>V-Q Scan</td>
</tr>
<tr>
<td>Abdominal USS</td>
</tr>
</tbody>
</table>

Conclusions: PH is associated with a poor prognosis. The most common cause in our population was LH disease. However in patients without LH disease, less than a quarter had further investigations to exclude potentially curable CTEPH.
P937 Pulmonary arterial hypertension prototype for national protocol and registry
Mohsen Malekshahmood1, Funak Fihomi2, Babak Sharifkhadani1, Mohammad Reza Masjedi1, 1Pulmonary and Critical Care, National Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran; 2Clinical Pharmacy, National Research Institute of Tuberculosis and Lung Disease, Tehran, Islamic Republic of Iran

Background: Pulmonary Hypertension (PH) has been defined as an increase in mean pulmonary arterial pressure (PAP) ≥ 25 mmHg at rest as assessed by right heart catheterization. The idiopathic form so called idiopathic pulmonary arterial hypertension iPAH is a fatal disorder with a prevalence of 8.6 per million of population. In the current report we introduced a registry site for iPAH patients, named www.pah.ir for better delivery of subsidized antihypertensive medications (now only Bosentan).

Methods: The registry was opened since November 2009. The first step of this action is to add iPAH patient’s information with a username and password in the site. Data entry is only available to the physicians and healthcare organizations via internet that are given a personalized username & password for entry. Following the patient’s profile submission in the site, a scientific committee composed of a cardiologist and a pulmonologist who are selected by Ministry of Health (MOH), would then evaluate the data. The eligibility of the patient to receive the medications is announced in the site after evaluation. If a patient is eligible, 82% of bosentan cost is paid by MOH.

Results: Till now, one hundred and sixteen patients (82 females, 34 males) are registered. Measured mean pulmonary artery pressure by right heart catheterization was 69.24 ± 17 mmHg (ranging from 35 to 110 mmHg).

Conclusion: The first online Iranian registry program for iPAH patients has recently been started and it is believed that this national program will supply essential information for health care providers in the field.

P938 Pulmonary hypertension: The experience of a large UK district general hospital
Sarah Clarke, Gemma Swarbrick, Sally Baddeley, Julie Chadwick, Tareq Saba.
Department of Respiratory Medicine, Blackpool Victoria Hospital, Blackpool, Lancashire, United Kingdom

Introduction: Recent advances in therapy make early identification of patients with Pulmonary Hypertension (PH) important. The 2008 consensus statement reported an average UK treatment rate of 24.9 per million.1

Aim: Our institution is a District General Hospital serving a population of 330,000. Our aim was to compare our treatment rate to the national average since the appointment of a physician with an interest in PH.

Method: Retrospective case note review of patients attending our monthly PH clinic since 2006.

Results: We identified 102 Outpatient and 35 Inpatient referrals. 28 went on to receive specialist treatment for PH; mean age 66 (range 36-85); 24 female 4 male. Diagnoses: Chronic thromboembolic 10, Idiopathic 8, Collagen vascular disease 5, Congenital left to right shunt 2, COPD 2 and Portal hypertension 1. Haemodynamics (mean): Cardiac catheter: mean Pulmonary Artery Pressure (PAP) 66 mmHg (n=22, range 22-78), cardiac output 4.8 (n=21, range 2.5-7.7), cardiac index 2.83 (n=22, range 1.47-5.14) and pulmonary vascular resistance 760 (n=22, range 123-1600). Echocardiography: systolic PAP 66 mmHg (n= 23, range 11.8-40). Treatment: Oral Monotherapy 11, 3-Phosphotidylinositol 1, Combination therapy 10, Interolent of therapy 1, Pulmonary Endarterectomy 6, Transplant referral 4, Shunt repair 1.

Outcome: 18 out of 28 patients survive on medical and surgical therapies. This is equivalent to 54 patients treated per million, considerably higher than the national average [1].

Conclusion: Diagnosis and treatment rates for PH in the UK can be substantially improved in many areas by developing local services with the support of the regional Specialist centre.

Reference: 

P939 Stability of a new formulation of intravenous epoprostenol sodium
Olivier Lambert1, Dirk Bandilla1 2Technique Operations, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 3Global Quality Management, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland

Epoprostenol sodium with (undisclosed) excipients (epoprostenol XX) is a new formulation of epoprostenol, a pulmonary arterial hypertension treatment. This study assessed stability and determined shelf-life of epoprostenol XX. Stability of epoprostenol XX, either diluted for immediate use and tested at 25°C, 30°C and 40°C for up to 72 h, or following storage for up to 8 days at 5°C after reconstitution and immediate dilution with further exposure at 25°C and 30°C for up to 48 h, was assessed at 3,000, 15,000 and 60,000 ng/mL. Potency was measured by HPLC. The time period over which potency remained ≥ 90% relative to 100% at time 0, determined shelf-life. Relative potency of diluted epoprostenol XX for immediate use was temperature-dependent and remained ≥ 90% after storage at 25°C, 30°C and 40°C for 48h, 24h and 8h, respectively (3,000 ng/mL); 48h, 24h and 12h, respectively (15,000 ng/mL); and 72h, 48h and 24h, respectively (60,000 ng/mL).

The relative potency of reconstituted and immediately diluted epoprostenol XX after storage for 8 days at 5°C was ≥ 90% and remained ≥90% after further storage for 24-48h at 25°C or 30°C, depending on concentration. The table shows shelf-life of epoprostenol XX based on these results.

Table 1. Shelf-life of epoprostenol XX solutions for different conditions of use

Concentration

Maximum shelf-life of diluted solution

Diluted solution for immediate administration

Diluted solution stored for 8 days at 5°C

≥3,000ng/mL

and <15,000ng/mL

48h at 25°C / 24h at 30°C / 8h at 40°C

24h at 25°C / 24h at 30°C

≤15,000ng/mL

and <60,000ng/mL

48h at 25°C / 24h at 30°C / 12h at 40°C

48h at 25°C / 24h at 30°C

≤60,000ng/mL

72h at 25°C / 48h at 30°C / 24h at 40°C

48h at 25°C / 48h at 30°C

P940 Pulmonary arterial hypertension: Long term effects of oral ambrisentan on clinical status, exercise capacity and haemodynamics
Michele D’Alto, Emanuele Romeo, Paola Argierto, Anna Correria, Berardo Sarubbi, Antonello D’Andrea, Antonietta Caronna, Maria Pignatello, Nicola Grimaldi, Raffaella Calabresi, Maria Giovanni Russo, Cardiology, Second University of Naples, Monaldi Hospital, Naples, Italy

Aim: To evaluate the efficacy and safety of oral ambrisentan in adult patients with pulmonary arterial hypertension (PAH) by assessing its long term effects on clinical status, exercise capacity and cardiopulmonary haemodynamics.

Methods: This was a single-centre, open-label, single-arm, prospective study. Clinical status, resting transcutaneous oxygen saturation (SpO2), 6-minute walk distance, serum and RHC were assessed at baseline (before starting ambrisentan therapy) and at one year follow-up.

Results: Twenty-seven consecutive adult patients (18 female, age 51±11y) with PAH (15 with idiopathic, 7 with congenital heart disease-related disease and 5 with connective tissue-related PAH) were enrolled. No patient treated with ambrisentan developed aminotransferase concentrations >3 times the upper limit of normal. After 12-14 months of therapy, an improvement in clinical status, 6-minute walk distance, pro-brain natriuretic peptide and haemodynamics was observed.

Clinical and haemodynamic variables at baseline and after oral ambrisentan therapy

<table>
<thead>
<tr>
<th>Variable</th>
<th>Basal</th>
<th>Follow-up</th>
<th>p</th>
</tr>
</thead>
<tbody>
<tr>
<td>WHO FC</td>
<td>2.80±0.4</td>
<td>2.5±0.5</td>
<td>0.0027</td>
</tr>
<tr>
<td>6MWD (m)</td>
<td>322±66</td>
<td>350±62</td>
<td>0.0005</td>
</tr>
<tr>
<td>pAOP (mmHg)</td>
<td>58±535</td>
<td>392±315</td>
<td>0.008</td>
</tr>
<tr>
<td>Heart catheterisation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>mPAP (mmHg)</td>
<td>50±17</td>
<td>49±16</td>
<td>ns</td>
</tr>
<tr>
<td>CI (l/min/m2)</td>
<td>2.4±0.5</td>
<td>2.7±0.4</td>
<td>0.0001</td>
</tr>
<tr>
<td>PVR (Wood)</td>
<td>10±6</td>
<td>8±4</td>
<td>0.007</td>
</tr>
</tbody>
</table>

Conclusions: Long term ambrisentan therapy is safe and well tolerated at 12-month follow-up, resulting in a significant improvement in clinical status, exercise capacity and cardiopulmonary haemodynamics.

P941 Incidence of subdural hematoma in patients with pulmonary arterial hypertension (PAH) in two randomized controlled clinical trials
Gerald Simonneau1, Lie-Hu Hwang1, Simon Teal1, Nazzareno Galle1 2Department of Pneumology and TCC, Hospital Antoine Bicêtre, Paris, France; 3Institute of Cardiology, University of Bologna, Italy; 4Specialty Care Business Unit, Pfizer Inc., New York, United States

Background: Recent reports have emerged of increased incidence of subdural haematomata in patients with PAH, a serious adverse event with high mortality and morbidity. We evaluate the event rate in two randomized controlled trials, SUPER-1/2 and PACES-1/2.

Methods: In SUPER-1/2, 277 patients (IPAH, CTD-, CHD-PAH, WHO FC II-IV, mean baseline PVR 952±63 dynes/cm²) naive to targeted therapy received placebo or sildenafil 20/40/80mg TID for 12 weeks. In the open-label extension (OLE) phase patients were up-titrated (as tolerated) to 80mg TID. In PACES-1/2, 267 patients (IPAH, CTD-PAH, WHO FC I-IV, mean baseline PVR 810.5±63 dynes/cm²) were stable on IV epoprostenol received placebo or sildenafil (up-titrated to 80mg TID, as tolerated) for 16 weeks. Patients in both OLE trials received sildenafil for ≥3 years. Treatment with conventional agents (anticoagulants, diuretics, digoxin, oxygen, calcium-channel blockers) was permitted. We determined the annual event rate of subdural haematoma by treatment exposure in person-years. Patient days on therapy does not include days on placebo.

Results: 2 patients experienced subdural haematomata, both during OLE; one received placebo in PACES-1, one sildenafil 40mg TID in SUPER-1. Patients were
female, aged 58 and 62 years, diagnosed with IPAH, WHO FC III, mean PVR 557 (PACES-1) and 1073 dyne.s/cm$^5$ (SUPER-1) at baseline. Both patients received oral anticoagulants. In SUPER-1 and PACES-1, 73% and 82% of patients were on anticoagulants, respectively. Incidence of subdural haematoma in these 2 studies was 0.0015 events/patient-year.

Conclusion: Subdural haematoma is a rare event in PAH patients in these 2 randomized controlled trials.

P942
Long-term bosentan therapy improves exercise capacity and hemodynamics in sarcoidosis-associated pulmonary hypertension
Debbie Qua1, Veronica Palmiero2, Roxana Sulica3, 1Division of Pulmonary, Critical Care and Sleep Medicine, Beth Israel Medical Center, New York, NY, United States; 2Division of Pulmonary, Critical Care and Sleep Medicine, St. Luke’s-Roosevelt Hospital Center, New York, NY, United States

Introduction and Rationale
Therapeutic options in sarcoidosis-associated pulmonary hypertension (SHP) are limited. We evaluated the long-term efficacy of Bosentan in SHP.

Methods: Out of 60 consecutive patients with SHP retrospectively reviewed, 45 were eligible for Bosentan therapy and followed for 36 months. We recorded baseline characteristics, hemodynamics and 6-minute walk distance (6MWD) before/after treatment, side effects, and vital status. Statistical analysis was performed using Student t-test and 1-way ANOVA.

Results: There were 65% Blacks, 64% women, with mean age of 53 years. Most patients (62%) had pulmonary fibrosis, and mean diffusing capacity was 57%. Additional SHP therapy was required in 45% cases; bosentan was discontinued in 5 patients due to liver abnormalities (incidence 1%). One- and 3-year survival rates were 73% and 48%. In 29 patients that remained on bosentan at three years, there were significant improvements in the 6MWD (p=0.005) and hemodynamics.

Conclusions: A subset of SHP patients may benefit from bosentan therapy.

P943
First long-term experience with intravenous treprostinil administered by the implantable infusion pump LenusPro. A single-center pilot study
Regina Sterringer-Mascherbauer1, Veronika Eder1, Charlotte Huber1, Susanne Witsch1, Reinhold Fuegger2, Uwe Freischl2, Hans Joachim Nesser1, 1Department of Cardiology, Public Hospital Elisabethin Linz, Academic Teaching Center, Linz, Austria; 2Department of Surgery, Public Hospital Elisabethinen Linz, Academic Teaching Center, Linz, Austria

Introduction: Parenteral prostanooids are considered to be the most potent agents in the treatment of pulmonary arterial hypertension (PAH). However, administration of parenteral prostanooids with external pumps is technically challenging and associated with side effects such as infusion site pain with subcutaneous (s.c.) and possibly life-threatening catheter-related infections with intravenous (i.v.) administration. The Lenus Pro implantable infusion pump was specifically developed to overcome the drawbacks of s.c. administration. In 2010, we reported the first implantation of a Lenus Pro pump with a filling interval of 28 days.

Results: Between September 2010 and October 2011, 14 patients underwent implantation at our center. All patients had previously shown significant clinical response to s.c. Treprostinil but suffered from site pain. Implantations were performed under general anesthesia. After preparation of the pump pocket in the abdominal wall the pump was connected to the central venous access. No intraoperative complications occurred. Postoperatively two patients developed a mild seroma. No other complications especially no infections were observed. Up to now more than 100 refill procedures were performed.

Conclusions: This first pilot study demonstrates that i.v. Treprostinil, delivered by the implantable pump Lenus Pro®, is safe, effective and feasible in PAH patients transitioned from s.c. Treprostinil. Filling intervals of 28 days ensure optimal compliance and long-term management. The absence of side effects such as infusion site pain is associated with a dramatic increase in quality of life.

P944
An international survey of current pulmonary arterial hypertension (PAH) management
Joana Preston1, Barbara Himmnanz2, Nicholas Bowdren3, Henning Tiede4, 1Pulmonary and Critical Care and Sleep Medicine Departments, Tufts University School of Medicine, Tufts Medical Center, Boston, United States; 2Global Market Research Department, Bayer HealthCare Pharmaceuticals, Berlin, Germany; 3Healthcare Department, Ipsos MORI, London, United Kingdom; 4Medical Clinic 2, University of Giessen Lang Centre, Giessen, Germany

Background: The therapeutic approach to PAH is evolving, multiple classes of agents are available and physicians from expert centres and the community treat PAH according to different indications. Objectives: To compare therapeutic management of PAH between countries and explore physicians’ attitudes towards PAH-specific therapies.

Methods: Quantitative online survey conducted in 5 European countries, the US, and Canada during 2010. Physicians involved in PAH treatment decisions with experience in managing PAH for ≥2 years completed a perceptual questionnaire. Retrospective clinical records from last 5 patients (pts) seen by each physician were analysed.

Results: 472 physicians (43% cardiologists, 29% pulmonologists, 20% rheumatologists, and 8% internists), 62% based in pulmonary hypertension centres, entered data for 2360 pts. Among these, 51% had idiopathic PAH and 42% PAH associated with other conditions; 38% had significant physical limitation (NYHA functional class III/IV) at diagnosis. US pts were more likely to be diagnosed in the community (40%) than in Europe (60%) and Canada (28%). Globally, 73% were on PAH-specific therapy; with PDE-5 inhibitors, endothelin receptor antagonists, and prostacyclins used in 57%, 54%, and 26%, respectively. Of pts treated, 29% were on combination therapies; highest usage was in the US (36%) and lowest in Italy (17%). For 95% of pts, their physicians were satisfied to some degree with the current treatment regimen. Main reasons for satisfaction included symptom control or improvement and stable disease condition.

Conclusions: This multinational survey highlights significant differences in PAH management between countries and illustrates physicians’ perceptions of treating this condition.

P945
Comparison of the pharmacokinetic, pharmacodynamic, and safety profiles of three different formulations of intravenous epoprostenol sodium
Laurent Nicolas1, Marcelo Gutierrez2, Jasper Dingemans. Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland

A change in excipient of epoprostenol sodium, an i.v. pulmonary arterial hyperensive treatment, from glycine-mannitol (epoprostenol GM; Flolan®) to arginine-mannitol (epoprostenol AM, Veletri®) or to undisclosed excipients (epoprostenol XX) has led to improvements in stability of the latter two formulations.

The pharmacokinetic (PK), haemodynamic, safety, and tolerability profiles of these formulations were compared in this 2-part study. 20 healthy males in Part 1 and 20 different subjects in Part 2 received epoprostenol AM and epoprostenol XX, and epoprostenol GM and epoprostenol XX, respectively, in a crossover design, in sequential 2h i.v. infusions of 2, 4, 6 and 8 ng/kg/min.

PK profiles were assessed by analysing plasma concentration-time curves of the primary epoprostenol metabolites 6-keto-prostacyclin F1α (kPF) and 6,15-diketo-13,14-dihydro-prostacyclin F1α (ddPF) obtained after treatment with the different epoprostenol formulations. For Part 1, the ratio of the geometric means (90% CI) of AUC$_{0-\infty}$ calculated after epoprostenol AM and epoprostenol XX treatment was 0.91 (0.88–0.95) for kPF and 0.88 (0.84–0.92) for ddPF. For Part 2, the ratio of AUC$_{0-\infty}$, determined after epoprostenol GM and epoprostenol XX treatment was 0.97 (0.91–1.03) for kPF and 1.08 (1.02–1.14) for ddPF. Haemodynamic variables, assessed by echocardiography, showed similar increases in cardiac output, cardiac index, and heart rate for all formulations with maximum values attained after 6–8h. Almost all subjects reported ≥1 adverse event.

These results suggest the 3 formulations of i.v. epoprostenol sodium have the same PK, haemodynamic, safety, and tolerability profiles.

P946
Lack of relevant pharmacokinetic interactions between the new dual endothelin receptor antagonist macitentan and sildenafil in healthy subjects
Patricia Sidharta1, Paul van Giersbergen1, Michael Wolzt2, Jasper Dingemans3, 1Clinical Pharmacology, Actelion Pharmaceuticals Ltd., Allschwil, Switzerland; 2Clinical Pharmacology, Medical University of Vienna, Austria

Macitentan, a new potent, dual endothelin receptor antagonist (ERA), is a potential treatment for pulmonary arterial hypertension (PAH). As PAH treatment may involve combination therapy of an ERA with sildenafil, the mutual pharmacokinetic (PK) interactions were investigated using a randomised, 3-way crossover study
Thematic Poster Session
Halle A-23 - 12:50 - 14:40
Abstract printing supported by . Visit Chiesi at Stand B2.10

**P947**

**EPITOME-2: Evaluation of a new formulation of epoprostenol sodium in pulmonary arterial hypertension patients switched from an originally approved formulation**

Olivier Sitbon 1, Marion Delcroix 2, Emmanuel Bergot 2, Anco Boonstra 3, Pilar Escribano Sabías 4, Nazzareno Galí 5, John Granton 6, David Langleben 7, Thomas Pisters 8, Jean-Christophe Lemair 9, Gerald Simonneau 9, Service de Pneumologie, Hôpital Universitaire de Bicêtre, Université Paris-Sud, Le Kremlin Bicêtre, France; 2Pneumology, Academic Hospital Gauthuistberg, Leuven, Belgium; 3Service de Pneumologie, Hôpital Côte de Nacre–CHU, Caen, France; 4Pneumology, VU University Medical Center, Amsterdam, Netherlands; 5Servicio de Cardiología, Hospital Universitario 12 de Octubre, Madrid, Spain; 6Institute of Cardiology, University of Bologna, Italy; 7Pulmonary Hypertension Programme, Toronto General Hospital, Toronto, Canada; 8Service de Pneumologie, Chuj, Paris, France; 9Global Medical Science, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 10Effi-Stat, Effi-stat, Paris, France

**Introduction:** Epoprostenol sodium originally approved with glycine-mannitol excipients (epoprostenol GM; Flolan®) is an i.v. pulmonary arterial hypertension (PAH) treatment. Epoprostenol sodium with undisclosed excipients (epoprostenol XX) is a new formulation with improved room temperature stability and simplified storage requirements. EPITOME-2 is an ongoing PAH study evaluating switch from epoprostenol GM to epoprostenol XX.

**Methods:** Adult PAH patients treated with epoprostenol GM for ≥12 months and on a stable dose for the last 3 months were switched to epoprostenol XX. Changes from baseline to 3 months were evaluated for cardiac haemodynamic and clinical parameters, including pulmonary vascular resistance (PVR) and WHO functional class (FC). Safety and tolerability were also evaluated.

**Results:** Of the 42 patients enrolled, data are available for the first 10 completers. Mean (range) age was 45 (25-78) years and 5 were female. Mean (range) time from diagnosis was 10.57 (1.6-37.1) years. Following switch, patients remained on a stable epoprostenol XX dose at 3 months. There was no change from baseline to Month 3 in haemodynamics or WHO FC (table). Most AEs were typical of epoprostenol therapy.

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Baseline</th>
<th>Month 3</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dose, ng/kg/min</td>
<td>25.1 (7.58)</td>
<td>25.4 (7.58)</td>
</tr>
<tr>
<td>PVR, dyn.sec/cm²</td>
<td>666 (455-1164)</td>
<td>685 (356-1327)</td>
</tr>
<tr>
<td>mPAP, mmHg</td>
<td>54.7 (42-65)</td>
<td>55.0 (37-73)</td>
</tr>
<tr>
<td>CO, L/min</td>
<td>5.7 (4.6-6.7)</td>
<td>5.7 (5.6-7.4)</td>
</tr>
<tr>
<td>WHO FC I, II, III (n)</td>
<td>1.54</td>
<td>1.63</td>
</tr>
</tbody>
</table>

**Conclusions:** There are no indications thus far of unexpected safety, tolerability, efficacy or dosing issues arising from switching patients to epoprostenol XX.

**P948**

**Outcomes from use of targeted therapy in pulmonary hypertension associated with sarcoidosis (PHAS)**

John Canning, Colm McCabe, Joanna Pekpe-Zauba, Karen Sheares, Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom

Pulmonary hypertension is a recognised complication of sarcoidosis and may arise from several aetiological pathways. We report our experience of patients with PHAS Group V on targeted treatment. Retrospective study of patient outcomes with PHAS. All patients underwent right heart catheterisation satisfying criteria for diagnosis of PAH. We reviewed 16 patients, 10 of whom died in mean f/u 52m. Patients dichotomised into 2 groups (responders and non-responders) based on improvement in log n-proBNP and 6MWD within 6 months of therapy initiation. Treatment response was associated with a reduced risk of death. Cohort phenotypes suggest that treatment response may not be pined concomitant sarcoid stage, functional class, FVC or presence of extrapulmonary features. However elevation in PVR may possibly be associated with a favourable response. An RCT is indicated to evolve a larger cohort.

**P949**

**Ambrisentan for therapy of portopulmonary hypertension (POPH): Update on safety and efficacy**

Rodrigo Cortes-Coba, Karen Swanson, Michael Krowka, Pulmonary and Critical Care, Mayo Clinic, Rochester, MN, United States

**Aim:** To present an update of the long-term hemodynamic response and clinical outcomes of POPH patients treated with ambrisentan.

**Methods:** Observational study of POPH patients from 01/2007 to 12/2011 treated with ambrisentan. Clinical data, baseline and follow up transthoracic echocardiograms (TTE) and right heart catheterisations (RHC) were accomplished and compared.

**Results:** A total of 27 patients with POPH were started on ambrisentan (female=15). Mean age (IQR) was 56 (53-60). Median follow up 874 days (472-1548). Median time on ambrisentan 391 days (259-839). Ten patients underwent liver transplantation successfully. Nine out of 27 patients died, 7 deaths due to complications of chronic liver disease, one patient of sepsis, and one died of an acute coronary syndrome. Follow up RHC data were available in 20 patients. Mean pulmonary artery pressure (mPAP) improved from 42 mmHg (35-57) to 38.5 (28-43.5), p=0.001; pulmonary vascular resistance (PVR) improved from 434 dynes-cm⁻5 (311-611) to 228 (154-361), p=0.001; and cardiac output increased from 6 L/min (5.4-7.4) to 7.9 (6.4-9.2), p=0.005. TTE data showed that RV size and function improved in 19 and 18 patients respectively. Ambrisentan was well tolerated in all but one patient who developed severe edema and required discontinuation after 2 weeks of initiation. No significant elevation of transaminases requiring discontinuation of the medication was identified.

**Conclusion:** In this cohort of patients with POPH, ambrisentan proved to be safe and efficacious for the therapy of POPH patients. Ambrisentan resulted in significant improvement in hemodynamics and normalization of RV size, function and PVR in the majority of the patients.

**P950**

**Lack of relevant pharmacokinetic and pharmacodynamic interactions between the new dual endothelin receptor antagonist macitentan and warfarin in healthy subjects**

Patricia Suhorta 1, Hartmut Dietrich 2, Jasper Dingemanse 1, 1Clinical Pharmacology, Actelion Pharmaceuticals Ltd, Allschwil, Switzerland; 2ClinPharmCologne, MEDA Manufacturing GmbH, Cologne, Germany

Macitentan, a new, potent, dual endothelin receptor antagonist (ERA), is a potential treatment for pulmonary arterial hypertension (PAH). In this study (AC-055-105),
the effect of macitentan on the pharmacokinetics (PK) and pharmacodynamics (PD) of a single dose of warfarin was investigated in 14 healthy male subjects. Subjects received treatment sequence A/B or B/A separated by a 2-week washout. Treatment A: macitentan for 8 days (loading dose of 30 mg, thereafter 10 mg o.d.). On Day 4, a single dose of 25 mg warfarin was given with macitentan. Treatment B: A single dose of 25 mg warfarin on Day 1. Blood samples were assessed for PK (R- and S-warfarin) and PD (INR and Factor VII). Plasma trough levels of macitentan and its active metabolite, ACT-132577, were determined. Twelve subjects were included in the PK/PD analysis. The plasma concentration-time profiles of R- and S-warfarin (Figure 1) and PD parameters of INR and Factor VII were comparable between treatments.

Warfarin did not impact the trough levels of macitentan and ACT-132577. Both treatments were well tolerated. Based on these results, no dose correction of macitentan or warfarin is needed when using these drugs together.

P951 Absorption behavior of riociguat (BAY 63-2521): Bioavailability, food effects, and dose-proportionality
Corina Becker1, Reinier Frey1, Christiane Hesse1, Sigrun Unger1
Michael Reber1, Wolfgang Mueckl1, 2Clinical Pharmacology Department, Bayer AG, Wuppertal, Germany; 2Global Biostatistics Department, Bayer Pharma AG, Wuppertal, Germany

Introduction: Riociguat, an oral soluble guanylate cyclase (sGC) stimulator, is currently investigated in the treatment of PH. Riociguat increases cGMP production through a novel dual mode of action: direct NO-independent sGC stimulation and increasing sGC sensitivity to low NO levels.

Aim: To characterize the biopharmaceutical properties of riociguat including absolute bioavailability (BA), interaction with food, and dose-proportionality.

Methods: Pharmacokinetics (PK) following IV and oral administration of immediate release tablets were characterized in 3 open-label, randomized, crossover studies in healthy male subjects; absolute BA (n=22), food effect at 2.5 mg (n=24), and dose-proportionality over 0.5–2.5 mg (n=24). Safety and tolerability were also assessed.

Results: Absolute BA was 94% (90% CI: 83–107). A high-fat breakfast delayed absorption with little effect on the extent of riociguat absorption (ratio AUCoral/AUCi.v. 88% CI: 82–95). PK were dose-proportional over 0.5–2.5 mg (common slope of AUC 1.09 [90%CI: 1.04–1.14]; Cmax 0.98 [90% CI: 0.93–1.04]). Intra-individual variability was low (G-CV AUC 30%, Cmax G-CV 65%). Riociguat was well tolerated in all studies. Adverse events were as expected from the mode of action.

Conclusion: Riociguat shows complete oral absorption, and no clinically relevant food effect. At 0.5–2.5 mg, riociguat systemic exposure increased dose-proportionally and increasing sGC sensitivity to low NO levels.

P952 Effect of ambrisentan, bosentan and macitentan on human hepatic uptake and efflux transporters
Hunter Gillies1, Irene Lepisi2, Jia Hao1, Adrian Ray2
1Clinical Research, Gilead Sciences Inc, Foster City, CA, United States; 2Drug Metabolism, Gilead Sciences Inc, Foster City, CA, United States

Background: The putative mechanism for hepatic adverse reactions observed with bosentan, an endothelin receptor antagonist (ERA), is inhibition of the hepatic transport of bile salts (Fattinger K 2003). The ERA ambrisentan has a low risk of hepatic adverse reactions.

Objective: Bosentan, ambrisentan and macitentan, an experimental ERA in clinical development, were tested for inhibition of hepatic transporters in vitro.

Methods: Inhibition constants (IC50) were measured for human BSEP, sodium taurocholate cotransporting polypeptide (NTCP), multidrug resistance protein 2 (MRP2), P-glycoprotein (Pgp), breast cancer resistance protein (BCRP), organic anion-transporting polypeptide IB1 (OATP1B1), and OATP1B3 in transfected cell-lines. Known inhibitors were used as positive controls.

Results: The most potent inhibition observed was for OATP1B1 (range 2 μM to 47 μM). Ambrisentan had no measurable effect on BSEP and NTCP while inhibition was observed for bosentan and macitentan. The most potent inhibition of these transporters was observed for macitentan with IC50 values of 12 and 8 μM for BSEP and NTCP, respectively.

Conclusions: Macitentan inhibited hepatic transporters the greatest whilst ambrisentan showed little or no effect.

P953 Bosentan influence on catecholamines levels in patients with idiopathic arterial pulmonary hypertension
Systemic Hypertension, Russian Cardiology Research-and-Production Complex, Moscow, Russian Federation

Aim: To assess the influence of endothelin receptor antagonist Bosentan on catecholamines levels in pts with idiopathic pulmonary arterial hypertension (IPAH).

Methods: In the single-center comparative study we included 35 pts aged 35,2±6,9 yrs with IPAH confirmed by RHC (WHO Functional Class (FC) II-IV) without systemic inflammation signs. On top of stable therapy with anticoagulants, diuretics, glycosides, calcium antagonists for at least 3 months, Bosentan therapy was started 62,5 mg twice daily for 4 wks. At wk4 the pts were randomized 1:1 by the envelope method to bosentan 125 or 250 mg/day. At baseline, at wk3 and wk12 visits the pts underwent the clinical and lab assessment, including catecholamines (HPLC).

Results: At baseline IPAH groups were comparable by age, sex, disease duration, hemodynamic parameters. In both groups the levels of norepinephrine were significantly higher than normal values (139,9±1,2). Otherwise the epinephrine levels were decreased as compared with controls (69,4±1,2).

Conclusion: In IPAH pts Bosentan therapy influenced on catecholamines levels by significant reduction of initially increased norepinephrine levels. This effect was more pronounced in Pts treated with Bosentan 125mg daily.

P954 Endothelin-1 downregulates BMP signaling in pulmonary artery smooth muscle cells
Hidekazu Maruyama1, Celine Dewachter1, Asma Belhaj 1, Benoit Rondelet 1, Myriam Remmelink2, Jean-Luc Vachiery3, Robert Naeije 1, Laurence Dewachter1, 4Physiopathology Laboratory, Université Libre de Bruxelles, Brussels, Belgium; 2Service d’Anatomie Pathologique, CUB-ULB Hopital Erasme, Brussels, Belgium; 3Pulmonary Vascular Diseases Clinic, CUB-ULB Hopital Erasme, Brussels, Belgium

Increased endothelin-1 (ET-1) and decreased bone morphogenetic protein (BMP) receptor type 2 (BMPR2) signaling pathways have been shown to be implicated in the pathogenesis of pulmonary arterial hypertension (PAH). However, little is known about the interaction between these two signaling pathways and its implication in the generation of altered pulmonary artery smooth muscle cell (PA-SCM) phenotype in PAH.

We further explored BMP signaling in PA-SCMs isolated from PAH patients and the effects of ET-1 treatment on the expressions of BMPR2, BMP agonists (BMP4) and antagonists (gremlin-1, gremelin-2 and noggin) in PA-SCMs.

We therefore quantified, by RTQ-PCR, the gene expressions of BMPR2, BMP agonists and antagonists in primary cultures of PA-SCMs isolated from PAH patients (n=4) and controls (n=9). We evaluated the effects of increasing concentrations of
ET-1 (10-6M and 10-7M) on the expression of these BMP signaling members in control PA-SMCs.

PA-SMCs isolated from PAH patients presented with decreased BMPR2 gene expression, while gene expressions of gremlin-1, gremlin-2 and noggin increased in PA-SMCs isolated from PAH patients compared to controls. BMP4 gene expression increased in PA-SMCs isolated from PAH patients. Stimulation of control PA-SMCs with ET-1 induced an increase in mRNA encoding BMP antagonists (gremlin-1, gremlin-2 and noggin), while BMPR2 gene expression decreased dose-dependently. However, in ET-1-treated PA-SMCs, BMP4 expression did not change. After ET-1 treatment, levels of BMPR2 and BMP antagonists were similar as those observed in PA-SMCs isolated from PAH patients.

Endothelium-derived ET-1 seems to contribute to altered BMPR2 signaling observed in PAH patients.